<DOC>
	<DOCNO>NCT01377870</DOCNO>
	<brief_summary>Multiple sclerosis multifocal inflammatory disease central nervous system affect young individual cause paralysis limb , sensation , visual sphincter problem . The disease cause autoimmune mechanism , ie immune system produce antibody cell attack self myelin antigen , cause therefore demyelination . The disease clinically evident relapse neurological disability due dysfunction area ( plaque multiple sclerosis ) damage myelin occur . Disability accumulate time disease enters progressive phase due damage axon irreversible neurodegeneration . Although , effective immunotherapy exist downregulate autoimmune anti-myelin reactivity reduce rate relapse MS ( like Copaxone interferon ) , effective mean today stop progression disability induce rebuild destroy myelin.Adult bone marrow derive stromal cell ( MSC ) show induce similar ( neuronal stem cell ) immunomodulatory neuroregenerative effect show laboratory induce neuroprotection animal model chronic experimental autoimmune encephalomyelitis ( EAE ) . These bone marrow derive MSCs offer practical advantage clinical therapeutic application , since obtain adult bone marrow therefore patient donor , without danger rejection cell . In addition , MSCs carry safer profile less prone malignant transformation . Our center perform clinical trial intra venous transplantation bone marrow derive mesenchymal stem cell.our purpose evaluate safety feasibility cell transplantation 1year following .</brief_summary>
	<brief_title>Evaluation Autologous Mesenchymal Stem Cell Transplantation ( Effects Side Effects ) Multiple Sclerosis</brief_title>
	<detailed_description>In clinical trial 30 patient multiple sclerosis drug resistance take apart.Based inclusion exclusion criterion patient chosen.Bone marrow aspiration do local anesthesia.Patients randomly divide 2 group : case control . Then mesenchymal stem cell separate prepared transplant intravenous injection patient case group cell obtain patient control group frozen inject 6 month . Patients follow Evaluation EDSS MSFC RAO Test brain cervical MRI quality life questionnaire 1th 3th 6th 12th month transplantation.all test do transplantation basic evaluation .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Both gender Age : 1855years Duration disease : 210 year Relapsing remit drug resistance EDSS : 36.5 Resistance immunomodulatory cytotoxic drug : At least 12 sever relapse 1 year drug treatment At least increase 1 point EDSS 1 year drug treatment Secondary progressive relapse multiple sclerosis Primary progressive MS relapse GAD positive enhancement Secondary progressive MS relapse Secondary progressive MS without relapse : progression disease 1 point increase EDSS last 18 month Pregnancy positive test Under treatment cytotoxic drug time last 3 month Under treatment immunomodulatory drug time last month Relapse disease 30 day less 30 day transplantation Primary progressive MS relapse GAD positive enhancement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>multiple sclerosis mesenchymal stem cell intravenous injection</keyword>
</DOC>